



Appendix 4D

Half-year report

Name of entity

INTEGRATED RESEARCH LIMITED		
ABN	Reporting period (half-year ended)	Previous corresponding period (half-year ended)
76 003 588 449	31 December 2023	31 December 2022

For announcement to the market

Extracts from this report for announcement to the market

					A\$000
Revenues from ordinary activities	Up	6%	to		40,844
Profit before tax attributable to members	Up	274%	to		11,986
Net profit for the period attributable to members	Up	248%	to		11,181

Dividends (distributions)	Amount per security	Franked amount per security
Interim dividend	Nil	N/A
Previous corresponding period	Nil	N/A

Brief explanation of results

Please refer to page 2 'Review of Operations' for an explanation of the results. This information should be read in conjunction with Integrated Research Limited 2023 Annual Report.
The information provided in this report contains all the information required by ASX Listing Rule 4.2A.

NTA backing	December 2023 Cents	December 2022 Cents
Net tangible asset backing per ordinary security	40.75	34.93

Dividends	December 2023 \$'000	December 2022 \$'000
No interim dividend has been declared for the current period	Nil	Nil
Total dividends provided for or paid	Nil	Nil



**INTEGRATED RESEARCH LIMITED AND CONTROLLED
ENTITIES**

FOR THE HALF-YEAR ENDED
31 DECEMBER 2023

ABN: 76 003 588 449

ASX CODE: IRI

Contents

Directors' Report	1
Consolidated Interim Financial Report	
Consolidated Statement of Comprehensive Income	4
Consolidated Statement of Financial Position	5
Consolidated Statement of Changes in Equity	6
Consolidated Statement of Cash Flows	7
Notes to the Consolidated Financial Statements	8
Directors' Declaration	13
Auditor's Independence Declaration	14
Independent Auditor's Review Report	15

Directors' Report

The Directors present their report together with the consolidated financial report for the half-year ended 31 December 2023 and the review report thereon.

Directors

The Directors of Integrated Research Limited at any time during or since the end of the half-year are:

Peter Lloyd – Independent Non-Executive Director and Chairman
 John Ruthven – Managing Director and Chief Executive Officer
 Cathy Aston – Independent Non-Executive Director
 Mark Brayan – Independent Non-Executive Director (appointed 22 November 2023)
 Michael Hitz – Independent Non-Executive Director (appointed 23 October 2023)
 Allan Brackin – Independent Non-Executive Director (resigned 30 September 2023)
 Anne Myers – Independent Non-Executive Director (retired 22 November 2023)
 James Scott – Independent Non-Executive Director (resigned 30 January 2024)

Principal Activities

Integrated Research Limited's principal activities are the design, development, implementation and sale of systems and applications management computer software for business-critical computing, Unified Communication networks and Payment networks.

Half-Year Results

The following table summarises the key revenue, expense and profit results for the consolidated entity for the half-year ended 31 December 2023 compared to the previous corresponding period:

In thousands of AUD	2023	2022	Change %
Revenue from licence fees	28,439	26,374	8%
Revenue from maintenance fees	7,116	7,450	(4%)
Revenue from subscription fees	1,065	855	25%
Revenue from testing solution services	1,755	1,856	(5%)
Revenue from professional services	2,469	1,900	30%
Total revenue	40,844	38,435	6%
Total expenses	(28,524)	(36,251)	(21%)
Profit before finance income, other losses, and income tax	12,320	2,184	464%
Other losses	(1,412)	(17)	8,206%
Finance income	1,078	1,037	4%
Profit before tax	11,986	3,204	274%
Income tax (expense)/benefit ¹	(805)	13	(6,292%)
Net profit after income tax	11,181	3,217	248%

The Company reported profit after tax of \$11.2 million and revenue of \$40.8 million for the half year ended 31 December 2023. The result represents a 248% increase in net profit after tax and a 6% increase in revenue on the prior equivalent half. Strong revenue results from the Americas (up 33%), offset by declines in Europe (down 42%) and APAC (down 18%). Total Contract Value² ("TCV") of \$41.3 million was up 6% on the previous corresponding period noting that the first half was a strong period for renewal business. Of the TCV written in the current half, 10% was attributable to either new customers or new products sold to existing customers. There were 14 new customers added during the period. The Company's transact and infrastructure business have gathered momentum, growing 28% respectively period on period.

¹ The effective income tax expense/(benefit) rate is not 30% of pre-tax profit due to permanent differences including estimates for the R&D tax incentives and utilisation of unrealised deferred tax assets brought forward from prior periods.

² Total contract value means the total value of a revenue generating contract written in the period of performance less any residual value from a previous related contract. The value includes software licence and related maintenance, cloud, testing and consulting services.

Directors' Report (continued)

Review of Operations

Revenue

Revenue for the reporting period was \$40.8 million, an increase of 6% over the previous corresponding period. The following table presents Company revenue for each of the relevant product groups:

In thousands of AUD	2023	2022	Change %
Collaborate	17,766	20,414	(13%)
Infrastructure	10,868	8,523	28%
Transact	9,741	7,598	28%
Professional Services	2,469	1,900	30%
Total revenue	40,844	38,435	6%

The following table presents revenue in native currency by geographic segment:

	2023	2022	Change %
Americas (USD'000)	17,958	13,553	33%
Europe (£'000)	2,325	3,996	(42%)
Asia Pacific (A\$'000)	8,978	11,002	(18%)

Expenses

The Company's operating cost base decreased by 21% to \$28.5 million. The decrease in operating expenses was driven by a decrease of staff related costs, no depreciation & amortisation and reduced bad debt provisions.

The following table represents an analysis of product and technology expenses:

In thousands of AUD	2023	2022
Gross product and technology expenses ¹	6,672	11,177
Capitalisation of development expenses	-	(4,483)
Amortisation of capitalised expenses	-	5,265
Net product and technology expenses	6,672	11,959

¹Gross product and technology expenses include product, research and development and technology related operating expenses.

Cashflow

Cash receipts from customers was \$32.4 million for the reporting period with no new debtor factoring. Cash receipts were higher than the corresponding period due to higher TCV and lower receivable ageing.

For the financial year ended 30 June 2023, as detailed in the Directors' Report for that financial year, no dividends were paid to the holders of fully paid ordinary shares.

Statement of Financial Position

At 31 December 2023, the Company held \$21.5 million in cash (30 June 2023: \$18.6 million). Receivables were higher at the end of the period due to strong TCV towards the end of the period.

Directors' Report (continued)

Interim Dividend

The Board did not declare an interim dividend. The assessment of future dividends will be made after the annual results are available.

Lead Auditor's Independence Declaration under Section 307C of the Corporations Act 2001

The lead auditor's independence declaration is set out on page 14 and forms part of the Directors' Report for the half-year ended 31 December 2023.

Rounding off

Integrated Research Limited is of a kind referred to in ASIC Legislative instrument 2016/191 and in accordance with the Class Order, amounts in the financial report and Directors' Report have been rounded off to the nearest thousand dollars, unless otherwise stated.

Signed in accordance with a resolution of the Directors:



Peter Lloyd
Chairman



John Ruthven
Managing Director and Chief Executive Officer

Dated at North Sydney this 22nd day of February 2024.

Consolidated Statement of Comprehensive Income

For the half-year ended 31 December 2023

In thousands of AUD

	Note	December 2023	December 2022
Continuing Operations			
<i>Revenue from contracts with customers</i>			
Licence fees		28,439	26,374
Maintenance fees		7,116	7,450
Subscription fees		1,065	855
Testing solution services		1,755	1,856
Professional services		2,469	1,900
Total revenue	3	40,844	38,435
<i>Expenditure:</i>			
Product and technology expenses		(6,672)	(11,959)
Sales, professional services and marketing expenses		(19,016)	(20,215)
General and administration expenses		(2,836)	(4,077)
Total expenditure		(28,524)	(36,251)
Other losses		(1,412)	(17)
Profit before finance income and tax		10,908	2,167
Finance income		1,078	1,037
Profit before tax		11,986	3,204
Income tax (expense)/benefit		(805)	13
Profit for the period		11,181	3,217
Other comprehensive income			
Items that may be reclassified subsequently to profit			
Foreign exchange translation differences		(543)	359
Other comprehensive income for the period		(543)	359
Total comprehensive income for the period		10,638	3,576
<i>Profit attributable to:</i>			
Members of Integrated Research		11,181	3,217
<i>Total comprehensive income attributable to:</i>			
Members of Integrated Research		10,638	3,576
Earnings per share attributable to members of Integrated Research			
Basic earnings per share to ordinary equity holders (AUD cents)	4	6.43	1.86
Diluted earnings per share to ordinary equity holders (AUD cents)	4	6.37	1.86

The consolidated statement of comprehensive income is to be read in conjunction with the accompanying notes set out on pages 8 to 12.

Consolidated Statement of Financial Position

As at 31 December 2023

In thousands of AUD

	December 2023	June 2023
Current assets		
Cash and cash equivalents	21,535	18,553
Trade and other receivables	38,333	40,913
Current tax assets	776	127
Other current assets	2,285	3,457
Total current assets	62,929	63,050
Non-current assets		
Trade and other receivables	29,848	22,540
Other financial assets	1,365	1,400
Right-of-use assets	306	-
Deferred tax assets	1,289	1,509
Other non-current assets	1,077	1,213
Total non-current assets	33,885	26,662
Total assets	96,814	89,712
Current liabilities		
Trade and other payables	7,031	7,901
Provisions	2,464	3,451
Income tax liabilities	453	415
Deferred revenue	12,281	13,862
Lease liabilities	1,734	1,582
Total current liabilities	23,963	27,211
Non-current liabilities		
Provisions	869	935
Deferred revenue	-	220
Lease liabilities	825	1,470
Other financial liabilities	2	2
Total non-current liabilities	1,696	2,627
Total liabilities	25,659	29,838
Net assets	71,155	59,874
Equity		
Issued capital	1,667	1,667
Reserves	8,724	8,624
Retained earnings	60,764	49,583
Total equity attributable to members of Integrated Research	71,155	59,874

The consolidated statement of financial position is to be read in conjunction with the accompanying notes set out on pages 8 to 12.

Consolidated Statement of Changes in Equity

For the half-year ended 31 December 2023

In thousands of AUD

	Share Capital	Translation Reserve	Employee Benefits Reserve	Retained Earnings	Total
Balance as at 1 July 2023	1,667	1,870	6,754	49,583	59,874
Profit for the period	-	-	-	11,181	11,181
Other comprehensive income	-	(543)	-	-	(543)
Total comprehensive income for the period	-	(543)	-	11,181	10,638
Expensed employee options and performance rights	-	-	643	-	643
Balance at 31 December 2023	1,667	1,327	7,397	60,764	71,155

	Share Capital	Translation Reserve	Employee Benefits Reserve	Retained Earnings	Total
Balance as at 1 July 2022	1,667	641	5,996	78,809	87,113
Profit for the period	-	-	-	3,217	3,217
Other comprehensive income	-	359	-	-	359
Total comprehensive income for the period	-	359	-	3,217	3,576
Expensed employee options and performance rights	-	-	293	-	293
Balance at 31 December 2022	1,667	1,000	6,289	82,026	90,982

The consolidated statement of changes in equity is to be read in conjunction with the accompanying notes set out on pages 8 to 12.

Consolidated Statement of Cash Flows
 For the half-year ended 31 December 2023
 In thousands of AUD

	December 2023	December 2022
Cash flows from operating activities		
Cash receipts from customers	32,439	31,724
Cash paid to suppliers and employees	(27,729)	(29,907)
Cash generated from operations	4,710	1,817
Income taxes paid	(1,305)	(812)
Net cash from operating activities	3,405	1,005
Cash flows from investing activities		
Payments for capitalised development	-	(4,483)
Payments for property, plant and equipment	(3)	(198)
Interest received	1,133	1,117
Net cash used in investing activities	1,130	(3,564)
Cash flows from financing activities		
Payment of lease liabilities	(947)	(705)
Interest payments	(54)	(81)
Net cash used in financing activities	(1,001)	(786)
Net increase/(decrease) in cash and cash equivalents	3,534	(3,345)
Cash and cash equivalents at 1 July	18,553	12,329
Effects of exchange rate changes on cash	(552)	272
Cash and cash equivalents at 31 December	21,535	9,256

The consolidated statement of cash flows is to be read in conjunction with the accompanying notes set out on pages 8 to 12.

Notes to the Consolidated Financial Statements

For the half-year ended 31 December 2023

In thousands of AUD

Note 1. Significant accounting policies

a) Statement of Compliance

The half-year financial report is a general purpose financial report prepared in accordance with the Corporations Act 2001 and AASB 134 Interim Financial Reporting. Compliance with AASB 134 ensures compliance with International Financial Reporting Standard IAS 34 Interim Financial Reporting. The half-year report does not include notes of the type normally included in an annual financial report and should be read in conjunction with the most recent annual financial report.

b) Basis of Preparation

The interim financial report is prepared on the historical cost convention, with the exception of financial instruments for the purposes of cash flow hedges, which are at fair value. All amounts are presented in Australian dollars unless otherwise stated.

Integrated Research Limited is a for-profit Company limited by ordinary shares.

Integrated Research Limited is of a kind referred to in ASIC Legislative instrument 2016/191. In accordance with that Class Order, amounts in the financial report and Directors' Report and the half-year financial report have been rounded off to the nearest thousand dollars, unless otherwise indicated.

New accounting standards and interpretations

The accounting policies and methods of computation adopted in the preparation of the half-year financial report are consistent with those adopted and disclosed in Integrated Research Limited's 2023 annual financial report. These accounting policies are consistent with Australian Accounting Standards and with International Financial Reporting Standards.

Note 2. Segment information

The Chief Operating Decision Maker, “CODM”, (being the Chief Executive Officer) reviews a variety of information on the performance of Prognosis across the group for the purpose of resource allocation.

The principal geographical regions are The Americas – Operating from the United States with responsibility for the countries in North, Central and South America, Europe – operating from the United Kingdom and Germany with responsibility for the countries in Europe, Asia Pacific – operating from Australia and Singapore with responsibility for the countries in the rest of the world and Corporate Australia – with responsibility for research and development and corporate head office functions of the Company. Inter-segment pricing is determined on an arm’s length basis.

Information regarding these geographic regions is presented below.

In thousands of AUD	Americas		Europe		Asia Pacific		Corporate Australia ¹		Eliminations		Consolidated	
	2023	2022	2023	2022	2023	2022	2023	2022	2023	2022	2023	2022
Sales to customers outside the consolidated entity	27,404	20,310	4,462	7,122	8,978	11,002	-	-	-	-	40,844	38,435
Inter-region revenue ²	-	-	-	-	-	-	23,869	18,687	(23,869)	(18,687)	-	-
Total regional revenue	27,404	20,310	4,462	7,122	8,978	11,002	23,869	18,687	(23,869)	(18,687)	40,844	38,435

In local currency ³	Americas (USD)		Europe (UK Sterling)	
	2023	2022	2023	2022
Sales to customers outside the consolidated entity	17,958	13,553	2,325	3,996
Inter-region revenue ²	-	-	-	-
Total regional revenue	17,958	13,553	2,325	3,996

¹ Corporate Australia includes research and development, hedging and corporate head office functions of Integrated Research Limited.

² Inter-region revenue represents the cost of sale of licence from Corporate Australia to its related sales functions.

³ Segment results represented in local currencies.

Note 3. Revenue from contracts with customers

Information regarding the disaggregation of the Company’s revenues from contracts with customers is presented below.

In thousands of AUD	Consolidated	Consolidated
	December 2023	December 2022
Timing of revenue recognition		
At a point in time	28,439	26,374
Over time	12,405	12,061
Total Revenue from contracts with customers	40,844	38,435
Type of product group		
Collaborate	17,766	20,414
Infrastructure	10,868	8,523
Transact	9,741	7,598
Professional Services	2,469	1,900
Total revenue	40,844	38,435

Note 4. Earnings per Share

Basic earnings per share

The calculation of basic earnings per share for the half-year ended 31 December 2023 was based on the profit attributable to ordinary shareholders of \$11,181,000 (half-year ended 31 December 2022: \$3,217,000) and a weighted average number of ordinary shares outstanding during the half-year ended 31 December 2023 of 173,949,026 (half-year ended 31 December 2022 of 172,775,305).

Diluted earnings per share

The calculation of diluted earnings per share for the half-year ended 31 December 2023 was based on the profit attributable to ordinary shareholders of \$11,181,000 (half-year ended 31 December 2022: \$3,217,000) and a weighted average number of ordinary shares (diluted with the probability of outstanding options and rights vesting) outstanding during the half-year ended 31 December 2023 of 175,537,645 (half-year ended 31 December 2022: 172,799,939).

Note 5. Employee Equity benefits

Performance Rights and Options Plan – November 2011

The consolidated entity has a performance rights and options plan that enables Integrated Research Limited to offer performance rights and options to eligible employees to obtain shares in Integrated Research Limited contingent upon performance conditions being met. The performance conditions may be a service period only or a service period and either a net profit after tax or total shareholder return hurdle. The performance rights are automatically exercised into shares upon the performance conditions being met at zero cost. Options are exercisable by employees after the vesting date but before the expiry date (which is five years from the grant date) at their exercise price. The following instruments were granted during the period:

Grant Date	Type	Quantity	Exercise price	Expiry date
August 2023	Performance rights	265,000	-	September 2025
October 2023	Performance rights	4,872,158	-	September 2026
November 2023	Performance rights	1,648,720	-	August 2026

The fair value of the Instruments including assumptions used are as follows:

Grant date	Aug 2023	Oct 2023	Nov 2023
Fair value at measurement date	\$0.400	\$0.330	\$0.074 (T1)
	- \$0.440		\$0.066 (T2)
			\$0.054 (T3)
Share price	\$0.400	\$0.330	\$0.300
	- \$0.440		
Exercise price	Nil	Nil	nil
Expected volatility	N/A	N/A	64.74%
Contractual life (expressed in days)	766	1,077	1,014
Expected dividends	0.0%	0.0%	0.0%
Risk-free interest rate (based on 3 year treasury bonds)	N/A	N/A	3.97%
			\$0.80 (T1)
Performance hurdles - IRI share price at testing date	N/A	N/A	\$1.20 (T2)
			\$1.60 (T3)
			Aug-24 (T1)
Testing date	N/A	N/A	Aug-25 (T2)
			Aug-26 (T3)
Model Used	Black Scholes	Black Scholes	Monte Carlo

The fair values of services received in return for performance rights and options granted to employees is measured by reference to the fair value of rights granted.

The following instruments were outstanding as at 31 December 2023:

Grant Date	Type	Quantity	Exercise price	Expiry date
August 2021	Options	1,147,332	\$1.98	August 2026
November 2021	Performance rights	186,477	-	August 2024
May 2022	Performance rights	6,734	-	August 2024
November 2022	Performance rights	90,400	-	August 2025
November 2022 ¹	Performance rights	1,589,012	-	August 2025
December 2022	Performance rights	2,468,531	-	September 2025
August 2023	Performance rights	96,667	-	September 2025
October 2023	Performance rights	4,834,157	-	September 2026
November 2023 ²	Performance rights	1,648,720	-	August 2026

¹ Performance rights allocated have market hurdles attached to their vesting conditions to be tested in August 2023, August 2024 and August 2025.

² Performance rights allocated have market hurdles attached to their vesting conditions to be tested in August 2024, August 2025 and August 2026.

During the period, the following performance rights were exercised into ordinary shares for nil consideration.

Grant Date	Number of Rights	Expiry date
September 2020	5,921	August 2023
November 2020	17,424	August 2023
November 2021	179,677	August 2024
November 2022	45,200	August 2025
December 2022	1,231,386	September 2025
August 2023	48,333	September 2025

Note 6. Financial Instruments

Forward foreign exchange contracts

The consolidated entity is exposed to foreign currency risk on sales and purchases that are denominated in a currency other than the AUD. The currencies giving rise to this risk are primarily United States Dollar, UK Sterling and the Euro.

The consolidated entity uses forward exchange contracts to hedge its foreign currency risk. The forward exchange contracts have maturities of less than two years after the reporting date. This was in place during 2022, however no hedging contracts were outstanding for 2023.

The consolidated entity classifies its option and forward exchange contracts hedging forecasted transactions as cash flow hedges and measures them at fair value. The following table details the option and forward foreign currency contracts outstanding as at reporting date:

Outstanding contracts	Average Exchange Rate		Foreign Currency		Contract Value		Fair Value	
	2023	2022	2023 FC'000	2022 FC'000	2023 A\$'000	2022 A\$'000	2023 A\$'000	2022 A\$'000
FX Forwards								
<u>Sell US Dollar</u>								
Less than 3 months	-	0.71	-	750	-	1,058	-	(48)
3 to 6 months	-	0.72	-	750	-	1,043	-	(59)
							-	(107)

These hedge assets and liabilities were classified as a level 2 fair value measurement, being derived from inputs provided from financial institutes, rather than quoted prices that are observable for the asset either directly (i.e. as prices) or indirectly (i.e. derived from prices). The fair value measurement of the over-the-counter forward contract would not qualify as Level 1 as there was not a quoted price for the actual contract, even though data used to value the contract may be derived entirely from active foreign-exchange and interest-rate market.

Note 6. Financial Instruments (continued)

Fair value of financial instruments

The carrying value of financial assets and financial liabilities of the consolidated entity is a reasonable approximation of their fair value.

Financial assets

For non-current trade debtors Integrated Research Limited has considered a discount rate to recognise the net present value of the debtors. Level 3 inputs have been considered including corporate borrowing rates, size of the customer, jurisdiction of the customer and historical default rates. A discounted cashflow model was used to derive the fair value. The range of discount rates was between 3.5% to 9.75%.

Credit risk management

Credit risk refers to the risk that a counterparty will default on its contractual obligations resulting in financial loss to the consolidated entity. The consolidated entity has adopted a policy of only dealing with creditworthy counterparties and obtaining sufficient collateral where appropriate, as a means of mitigating the risk of financial loss from defaults.

Trade receivables consist of a large number of customers, spread across diverse industries and geographical areas. The largest single counterparty balance with any one customer at 31 December 2023 was \$9.8 million (30 June 2023: \$2.7 million). Ongoing credit evaluation is performed on the financial condition of accounts.

The Company has a program to sell selected account receivable balances to a third party without recourse. There were no sales of accounts receivables during the current or prior comparative reporting period. The Company continues to bear maintenance support obligations to the end customers which are carried as a liability in the deferred revenue account of the Company's balance sheet of \$0.1 million (30 June 2023: \$0.5 million).

The credit risk on liquid funds and derivative financial instruments is limited because the counterparties are banks with high credit ratings assigned by international credit-rating agencies.

Note 7. Contingent liabilities

There were no contingent liabilities as at 31 December 2023.

Note 8. Subsequent events

There were no events after the interim balance sheet date which are expected to have a material effect on the consolidated entity's financial position.

Directors' Declaration

In accordance with a resolution of the directors of Integrated Research Limited:

In the opinion of the directors:

- a) The financial statements and notes of Integrated Research Limited for the half-year ended 31 December 2023 are in accordance with the Corporations Act 2001, including:
 - (i) Giving a true and fair view of the consolidated entity's financial position as at 31 December 2023 and of its performance for the half-year ended on that date; and
 - (ii) Complying with Accounting Standards and the Corporations Regulations 2001.
- b) There are reasonable grounds to believe that Integrated Research Limited will be able to pay its debts as and when they become due and payable.

Dated at North Sydney this 22nd day of February 2024.

On behalf of the Directors



Peter Lloyd
Chairman



John Ruthven
Managing Director and Chief Executive Officer



Ernst & Young
200 George Street
Sydney NSW 2000 Australia
GPO Box 2646 Sydney NSW 2001

Tel: +61 2 9248 5555
Fax: +61 2 9248 5959
ey.com/au

**Building a better
working world**

Auditor's Independence Declaration to the Directors of Integrated Research Limited

As lead auditor for the review of Integrated Research Limited for the half-year ended 31 December 2023, I declare to the best of my knowledge and belief, there have been:

- a) No contraventions of the auditor independence requirements of the *Corporations Act 2001* in relation to the review;
- b) No contraventions of any applicable code of professional conduct in relation to the review; and
- c) No non-audit services provided that contravene any applicable code of professional conduct in relation to the review.

This declaration is in respect of Integrated Research Limited and the entities it controlled during the financial period.

Ernst & Young

Julian M. O'Brien
Partner
22 February 2024



**Building a better
working world**

Ernst & Young
200 George Street
Sydney NSW 2000 Australia
GPO Box 2646 Sydney NSW 2001

Tel: +61 2 9248 5555
Fax: +61 2 9248 5959
ey.com/au

Independent Auditor's Review Report to the Members of Integrated Research Limited

Conclusion

We have reviewed the accompanying half-year financial report of Integrated Research Limited (the Company) and its subsidiaries (collectively the Group), which comprises the consolidated statement of financial position as at 31 December 2023, the consolidated statement of comprehensive income, consolidated statement of changes in equity and consolidated statement of cash flows for the half-year ended on that date, notes comprising a summary of significant accounting policies and other explanatory information, and the directors' declaration.

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the half-year financial report of the Group does not comply with the *Corporations Act 2001*, including:

- a. Giving a true and fair view of the consolidated financial position of the Group as at 31 December 2023 and of its consolidated financial performance for the half-year ended on that date; and
- b. Complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

Basis for conclusion

We conducted our review in accordance with ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity* (ASRE 2410). Our responsibilities are further described in the *Auditor's responsibilities for the review of the half-year financial report* section of our report. We are independent of the Group in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional and Ethical Standards Board's *APES 110 Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to our audit of the annual financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.


Directors' Responsibilities for the half-year financial report

The directors of the Company are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the half-year financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

Auditor's responsibilities for the review of the half-year financial report

Our responsibility is to express a conclusion on the half-year financial report based on our review. ASRE 2410 requires us to conclude whether we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the *Corporations Act 2001* including giving a true and fair view of the Group's financial position as at 31 December 2023 and its performance for the half-year ended on that date, and complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Ernst & Young



Julian M. O'Brien
Partner
Sydney
22 February 2024